News & Updates

Show Multimedia Only
Response to therapy higher in clinical trial than real-world RCC patients

Response to therapy higher in clinical trial than real-world RCC patients

22 Mar 2023

Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.

Response to therapy higher in clinical trial than real-world RCC patients

22 Mar 2023
CBT, mindfulness help improve sexual outcomes in prostate cancer

CBT, mindfulness help improve sexual outcomes in prostate cancer

21 Mar 2023
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy

Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy

13 Mar 2023

For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.

Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy

13 Mar 2023
Weight status influences urinary function recovery after radical prostatectomy

Weight status influences urinary function recovery after radical prostatectomy

10 Mar 2023

Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.

Weight status influences urinary function recovery after radical prostatectomy

10 Mar 2023
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?

Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?

10 Mar 2023

In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.

Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?

10 Mar 2023
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy

Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy

08 Mar 2023 byStephen Padilla

Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.

Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy

08 Mar 2023